Phase III Trial of Enzastaurin for NHL Patients Initiated

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Phase III Trial of Enzastaurin for NHL Patients Initiated

INDIANAPOLIS—Eli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content